Outcomes of Oncologic Total Humeral Reconstruction.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-03-01 DOI:10.21873/anticanres.17494

Leilani Garayua-Cruz, Samuel E Broida, Mikaela H Sullivan, Mark E Morrey, Jonathan D Barlow, Joaquin Sanchez-Sotelo, Matthew T Houdek

{"title":"Outcomes of Oncologic Total Humeral Reconstruction.","authors":"Leilani Garayua-Cruz, Samuel E Broida, Mikaela H Sullivan, Mark E Morrey, Jonathan D Barlow, Joaquin Sanchez-Sotelo, Matthew T Houdek","doi":"10.21873/anticanres.17494","DOIUrl":null,"url":null,"abstract":"Background/aim: The humerus is the most common site for malignant tumors in the upper extremity. Rarely, a total humeral resection with combined replacements of both the shoulder and the elbow are necessary. The aim of this study was to evaluate outcomes after total humeral reconstruction at our institution.Patients and methods: Nine patients (5 females, 4 males, mean age 48±26 years) with a malignant tumor of the humerus were included in this study. This included five endoprostheses and four allograft prosthetic composites.Results: Postoperative complications occurred in eight patients, most commonly deep vein thrombosis (DVT, n=3) and elbow contractures (n=3). Complications led to a revision procedure in one patient, with a cumulative incidence of failure of 25% at 5-years and a 5-year overall patient survival rate of 13%. At the most recent follow-up, the median Musculoskeletal Tumor Society Score was 50%.Conclusion: Total humerus reconstruction is a rare surgical procedure that is associated with a high rate of complications with relatively poor functional outcomes. However, this option does offer a means of limb salvage for patients with limited options.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1071-1075"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17494","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: The humerus is the most common site for malignant tumors in the upper extremity. Rarely, a total humeral resection with combined replacements of both the shoulder and the elbow are necessary. The aim of this study was to evaluate outcomes after total humeral reconstruction at our institution.

Patients and methods: Nine patients (5 females, 4 males, mean age 48±26 years) with a malignant tumor of the humerus were included in this study. This included five endoprostheses and four allograft prosthetic composites.

Results: Postoperative complications occurred in eight patients, most commonly deep vein thrombosis (DVT, n=3) and elbow contractures (n=3). Complications led to a revision procedure in one patient, with a cumulative incidence of failure of 25% at 5-years and a 5-year overall patient survival rate of 13%. At the most recent follow-up, the median Musculoskeletal Tumor Society Score was 50%.

Conclusion: Total humerus reconstruction is a rare surgical procedure that is associated with a high rate of complications with relatively poor functional outcomes. However, this option does offer a means of limb salvage for patients with limited options.

查看原文本刊更多论文

肿瘤全肱骨重建术的结果。

背景/目的：肱骨是上肢恶性肿瘤最常见的部位。很少，需要全肱骨切除术联合肩关节和肘关节置换术。本研究的目的是评估本院全肱骨重建的结果。患者和方法：9例肱骨恶性肿瘤患者，女性5例，男性4例，平均年龄48±26岁。其中包括5个内假体和4个同种异体移植假体复合材料。结果：8例患者出现术后并发症，最常见的是深静脉血栓形成（DVT, n=3）和肘关节挛缩（n=3）。并发症导致1例患者进行翻修手术，5年累计失败率为25%，5年总生存率为13%。在最近的随访中，肌肉骨骼肿瘤学会评分中位数为50%。结论：全肱骨重建术是一种罕见的外科手术，其并发症发生率高，功能预后相对较差。然而，这种选择确实为选择有限的患者提供了一种肢体保留手段。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.